Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001144204-16-077387
Filing Date
2016-01-27
Accepted
2016-01-27 21:38:51
Documents
2
Period of Report
2016-01-25

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT v429896_4.html 4  
1 OWNERSHIP DOCUMENT v429896_4.xml 4 5694
2 POWER OF ATTORNEY v429896_ex24.htm EX-24 8689
  Complete submission text file 0001144204-16-077387.txt   16084
Mailing Address 420 LEXINGTON AVENUE SUITE 350 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 350 NEW YORK NY 10170 212-584-4171
Caladrius Biosciences, Inc. (Issuer) CIK: 0000320017 (see all company filings)

EIN.: 222343568 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8090 Services-Misc Health & Allied Services, NEC

Mailing Address C/O CAMBREX CORP ONE MEADOWLANDS PLZ EAST RUTHERFORD NJ 07073
Business Address
KLOSK STEVEN M (Reporting) CIK: 0001192621 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33650 | Film No.: 161366455